Dry age-related macular degeneration: A currently unmet clinical need

Intractable and Rare Diseases Research

Volumn 1, Issue 3, 2012, Pages 103-114

  Girmens, Jean François ^a   José Sahel, José Alain ^a   Marazova, Katia ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

Age related macular degeneration; atrophy; clinical trials; degeneration; dry age related macular; geographic; treatment

Indexed keywords

EID: 84894663045     PISSN: 21863644     EISSN: 2186361x     Source Type: Journal    
DOI: 10.5582/irdr.2012.v1.3.103     Document Type: Article

References (80)

1. Zarbin MA. Current concepts in the pathogenesis of agerelated macular degeneration. Arch Ophthalmol. 2004; 122:598-614.
2. Augood CA, Vingerling JR, de Jong PT, Chakravarthy U, Seland J, Soubrane G, Tomazzoli L, Topouzis F, Bentham G, Rahu M, Vioque J, Young IS, Fletcher AE. Prevalence of age-related maculopathy in older Europeans: The European Eye Study (EUREYE). Arch Ophthalmol. 2006; 124:529-535.
3. Friedman DS, O'Colmain BJ, Munoz B, Tomany SC, McCarty C, de Jong PT, Nemesure B, Mitchell P, Kempen J. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004; 122:564-572.
4. Bird AC. The Bowman lecture. Towards an understanding of age-related macular disease. Eye (Lond). 2003; 17:457-466.
5. Kawasaki R, Yasuda M, Song SJ, Chen SJ, Jonas JB, Wang JJ, Mitchell P, Wong TY. The prevalence of agerelated macular degeneration in Asians: A systematic review and meta-analysis. Ophthalmology. 2010; 117:921-927.
6. Cheung CM, Tai ES, Kawasaki R, Tay WT, Lee JL, Hamzah H, Wong TY. Prevalence of and risk factors for age-related macular degeneration in a multiethnic Asian cohort. Arch Ophthalmol. 2012; 130:480-486.
7. Binder S, Stanzel BV, Krebs I, Glittenberg C. Transplantation of the RPE in AMD. Prog Retin Eye Res. 2007; 26:516-554.
8. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: The Beaver Dam Eye Study. Ophthalmology. 1997; 104:7-21.
9. Sunness JS. Geographic atrophy. In: Age Related Macular Degeneration (Berger JW, Fine SL, Maguire MG, eds.). Mosby, St. Louis, USA, 1999; p. 155.
10. Group AREDSR. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9. Arch Ophthalmol. 2001; 119(10):1439-1452.
11. Lindblad AS, Lloyd PC, Clemons TE, Gensler GR, Ferris FL, III, Klein ML, Armstrong JR. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol. 2009; 127:1168-1174.
12. Prahs P, Walter A, Regler R, Theisen-Kunde D, Birngruber R, Brinkmann R, Framme C. Selective retina therapy (SRT) in patients with geographic atrophy due to age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2010; 248:651-658.
13. Ding X, Patel M, Chan CC. Molecular pathology of agerelated macular degeneration. Prog Retin Eye Res. 2009; 28:1-18.
14. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004; 137:486-495.
15. Bernstein PS. Nutritional Interventions against Age Related Macular Degeneration. Acta Hortic. 2009; 841:103-112.
16. Hoh Kam J, Lenassi E, Jeffery G. Viewing ageing eyes: Diverse sites of amyloid Beta accumulation in the ageing mouse retina and the up-regulation of macrophages. PLoS One. 2010; 5:e13127.
17. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to agerelated macular degeneration. Proc Natl Acad Sci U S A. 2005; 102:7227-7232.
18. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, Henning AK, San Giovanni JP, Mane SM, Mayne ST, Bracken MB, Ferris FL, Ott J, Barnstable C, Hoh J. Complement factor H polymorphism in age-related macular degeneration. Science. 2005; 308:385-389.
19. Yang Z, Camp NJ, Sun H, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science. 2006; 314:992-993.
20. Haddad S, Chen CA, Santangelo SL, Seddon JM. The genetics of age-related macular degeneration: A review of progress to date. Surv Ophthalmol. 2006; 51:316-363.
21. Edwards AO, Ritter R, III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005; 308:421-424.
22. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, Spencer KL, Kwan SY, Noureddine M, Gilbert JR, Schnetz-Boutaud N, Agarwal A, Postel EA, Pericak Vance MA. Complement factor H variant increases the risk of age-related macular degeneration. Science. 2005; 308:419-421.
23. Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AJ, Gehrs K, Cramer K, Neel J, Bergeron J, Barile GR, Smith RT, Hageman GS, Dean M, Allikmets R. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet. 2006; 38:458-462.
24. Jakobsdottir J, Conley YP, Weeks DE, Mah TS, Ferrell RE, Gorin MB. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet. 2005; 77:389-407.
25. Rivera A, Fisher SA, Fritsche LG, Keilhauer CN, Lichtner P, Meitinger T, Weber BH. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum Mol Genet. 2005; 14:3227-3236.
26. Chen W, Stambolian D, Edwards AO, et al. Genetic variants near TIMP3and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci U S A. 2010; 107:7401-7406.
27. Cameron DJ, Yang Z, Gibbs D, et al. HTRA1 variant confers similar risks to geographic atrophy and neovascular age-related macular degeneration. Cell Cycle. 2007; 6:1122-1125.
28. Sepp T, Khan JC, Thurlby DA, Shahid H, Clayton DG, Moore AT, Bird AC, Yates JR. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest Ophthalmol Vis Sci. 2006; 47:536-540.
29. Yang Z, Stratton C, Francis PJ, et al. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med. 2008; 359:1456-1463.
30. Zhu D, Deng X, Xu J, Hinton DR. What determines the switch between atrophic and neovascular forms of age related macular degeneration? - the role of BMP4 induced senescence. Aging (Albany NY). 2009; 1:740-745.
31. Mitchell P, Wang JJ, Smith W, Leeder SR. Smoking and the 5-year incidence of age-related maculopathy: The Blue Mountains Eye Study. Arch Ophthalmol. 2002; 120:1357-1363.
32. Fujihara M, Nagai N, Sussan TE, Biswal S, Handa JT. Chronic cigarette smoke causes oxidative damage and apoptosis to retinal pigmented epithelial cells in mice. PLoS One. 2008; 3:e3119.
33. Schaumberg DA, Christen WG, Hankinson SE, Glynn RJ. Body mass index and the incidence of visually significant age-related maculopathy in men. Arch Ophthalmol. 2001; 119:1259-1265.
34. Boekhoorn SS, Vingerling JR, Hofman A, de Jong PT. Alcohol consumption and risk of aging macula disorder in a general population: The Rotterdam Study. Arch Ophthalmol. 2008; 126:834-839.
35. Klein R, Klein BE, Marino EK, Kuller LH, Furberg C, Burke GL, Hubbard LD. Early age-related maculopathy in the cardiovascular health study. Ophthalmology. 2003; 110:25-33.
36. Hjelmeland LM. Dark matters in AMD genetics: Epigenetics and stochasticity. Invest Ophthalmol Vis Sci. 2011; 52:1622-1631.
37. Hunter ASP, Cwanger A, Song Y, Zhang Z, Ying GS, Hunter AK, Dezoeten E, Dunaief JL. DNA Methylation Is Associated with Altered Gene Expression in AMD. Invest Ophthalmol Vis Sci. 2012; 53:2089-2105.
38. Hudson HL, Lane SS, Heier JS, Stulting RD, Singerman L, Lichter PR, Sternberg P, Chang DF. Implantable miniature telescope for the treatment of visual acuity loss resulting from end-stage age-related macular degeneration: 1-year results. Ophthalmology. 2006; 113:1987-2001.
39. AREDS Home Page. Age-related eye disease study. https://web.emmes.com/study/areds/(accessed May 2012).
40. Group AREDSR. Risk factors associated with age-related macular degeneration. A case-control study in the agerelated eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology. 2000; 107:2224-2232.
41. Group AREDSR. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol. 2001; 119:1417-1436.
42. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996; 334:1150-1155.
43. Seddon JM, Ajani UA, Sperduto RD, Hiller R, Blair N, Burton TC, Farber MD, Gragoudas ES, Haller J, Miller DT, Lawrence A, Walter W. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. Jama. 1994; 272:1413-1420.
44. Richer S, Stiles W, Statkute L, Pulido J, Frankowski J, Rudy D, Pei K, Tsipursky M, Nyland J. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: The Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry. 2004; 75:216-230.
45. Wong WT, Kam W, Cunningham D, Harrington M, Hammel K, Meyerle CB, Cukras C, Chew EY, Sadda SR, Ferris FL. Treatment of geographic atrophy by the topical administration of OT-551: Results of a phase II clinical trial. Invest Ophthalmol Vis Sci. 2010; 51:6131-6139.
46. Wen R, Tao W, Li Y, Sieving PA. CNTF and retina. Prog Retin Eye Res. 2012; 31:136-151.
47. Sieving PA, Caruso RC, Tao W, Coleman HR, Thompson DJ, Fullmer KR, Bush RA. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A. 2006; 103:3896-3901.
48. Emerich DF, Thanos CG. NT-501: An ophthalmic implant of polymer-encapsulated ciliary neurotrophic factorproducing cells. Curr Opin Mol Ther. 2008; 10:506-515.
49. Zhang K, Hopkins JJ, Heier JS, Birch DG, Halperin LS, Albini TA, Brown DM, Jaffe GJ, Tao W, Williams GA. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci U S A. 2011; 108:6241-6245.
50. Lonngren U, Napankangas U, Lafuente M, Mayor S, Lindqvist N, Vidal-Sanz M, Hallbook F. The growth factor response in ischemic rat retina and superior colliculus after brimonidine pre-treatment. Brain Res Bull. 2006; 71:208-218.
51. Collier RJ, Patel Y, Martin EA, Dembinska O, Hellberg M, Krueger DS, Kapin MA, Romano C. Agonists at the serotonin receptor (5-HT(1A)) protect the retina from severe photo-oxidative stress. Invest Ophthalmol Vis Sci. 2011; 52:2118-2126.
52. Rhoades KLPY, Collier RJ, Romano C. AL-8309, A Serotonin 5-HT1A Agonist, Protects RPE Cells From Oxidative Damage in ARVO E-Abstract 677. 2009, IVOS.
53. Wang YME, Hoang H, Rector R, Morgan S, Romano CCR. Inhibition of Complement Deposition by AL-8309A, a 5-HT1a Agonist, in the Rat Photic-Induced Retinopathy Model. IVOS. 2009; 50:ARVO E-Abstract 685.
54. Leveillard T, Mohand-Said S, Lorentz O, Hicks D, Fintz AC, Clerin E, Simonutti M, Forster V, Cavusoglu N, Chalmel F, Dolle P, Poch O, Lambrou G, Sahel JA. Identification and characterization of rod-derived cone viability factor. Nat Genet. 2004; 36:755-759.
55. Leveillard T, Sahel JA. Rod-derived cone viability factor for treating blinding diseases: From clinic to redox signaling. Sci Transl Med. 2010; 2:26ps16.
56. Golczak M, Kuksa V, Maeda T, Moise AR, Palczewski K. Positively charged retinoids are potent and selective inhibitors of the trans-cis isomerization in the retinoid (visual) cycle. Proc Natl Acad Sci U S A. 2005; 102:8162-8167.
57. Maeda A, Maeda T, Golczak M, Imanishi Y, Leahy P, Kubota R, Palczewski K. Effects of potent inhibitors of the retinoid cycle on visual function and photoreceptor protection from light damage in mice. Mol Pharmacol. 2006; 70:1220-1229.
58. Maeda A, Maeda T, Golczak M, Palczewski K. Retinopathy in mice induced by disrupted all-trans-retinal clearance. J Biol Chem. 2008; 283:26684-26693.
59. Kubota R, Boman NL, David R, Mallikaarjun S, Patil S, Birch D. Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator. Retina. 2012; 32:183-188.
60. Crabb JW, Miyagi M, Gu X, Shadrach K, West KA, Sakaguchi H, Kamei M, Hasan A, Yan L, Rayborn ME, Salomon RG, Hollyfield JG. Drusen proteome analysis: An approach to the etiology of age-related macular degeneration. Proc Natl Acad Sci U S A. 2002; 99:14682-14687.
61. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res. 2001; 20:705-732.
62. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002; 134:411-431.
63. Holland MC, Morikis D, Lambris JD. Synthetic small-molecule complement inhibitors. Curr Opin Investig Drugs. 2004; 5:1164-1173.
64. Chi ZL, Yoshida T, Lambris JD, Iwata T. Suppression of drusen formation by compstatin,a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv Exp Med Biol. 2010; 703:127-135.
65. Gehrs KM, Jackson JR, Brown EN, Allikmets R, Hageman GS. Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol. 2010; 128:349-358.
66. Rohrer B, Coughlin B, Bandyopadhyay M, Holers VM. Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization. J Ocul Pharmacol Ther. 2012; 28:402-409.
67. Allegretti M, Moriconi A, Beccari AR, Di Bitondo R, Bizzarri C, Bertini R, Colotta F. Targeting C5a: Recent advances in drug discovery. Curr Med Chem. 2005; 12: 217-236.
68. Zahn G, Vossmeyer D, Stragies R, Wills M, Wong CG, Loffler KU, Adamis AP, Knolle J. Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch Ophthalmol. 2009; 127:1329-1335.
69. Landa G, Rosen RB, Patel A, Lima VC, Tai KW, Perez VR, Aizman A, Garcia PM. Qualitativespectral OCT/SLO analysis of drusen change in dry age-related macular degeneration patients treated with Copaxone. J Ocul Pharmacol Ther. 2011; 27:77-82.
70. Sehgal SN. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplant Proc. 2003; 35:7S-14S.
71. Kaneko H, Dridi S, Tarallo V, et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature. 2011; 471:325-330.
72. Mohand-Said S, Hicks D, Leveillard T, Picaud S, Porto F, Sahel JA. Rod-cone interactions: Developmental and clinical significance. Prog Retin Eye Res. 2001; 20: 451-467.
73. Seiler MJ, Sagdullaev BT, Woch G, Thomas BB, Aramant RB. Transsynaptic virus tracing from host brain to subretinal transplants. Eur J Neurosci. 2005; 21:161-172.
74. Peyman GA, Blinder KJ, Paris CL, Alturki W, Nelson NC Jr, Desai U. A technique for retinal pigment epithelium transplantation for age-related macular degeneration secondary to extensive subfoveal scarring. Ophthalmic Surg. 1991; 22:102-108.
75. Carr AJ, Vugler AA, Hikita ST, Lawrence JM, Gias C, Chen LL, Buchholz DE, Ahmado A, Semo M, Smart MJ, Hasan S, da Cruz L, Johnson LV, Clegg DO, Coffey PJ. Protective effects of human iPS-derived retinal pigment epithelium cell transplantation in the retinal dystrophic rat. PLoS One. 2009; 4:e8152.
76. Falkner-Radler CI, Krebs I, Glittenberg C, Povazay B, Drexler W, Graf A, Binder S. Human retinal pigment epithelium (RPE) transplantation: Outcome after autologous RPE-choroid sheet and RPE cell-suspension in a randomised clinical study. Br J Ophthalmol. 2011; 95:370-375.
77. Busskamp V, Picaud S, Sahel JA, Roska B. Optogenetic therapy for retinitis pigmentosa. Gene Ther. 2012; 19:169-175.
78. Shannon RV. A model of safe levels for electrical stimulation. IEEE Trans Biomed Eng. 1992; 39:424-426.
79. Humayun MS, Weiland JD, Fujii GY, Greenberg R, Williamson R, Little J, Mech B, Cimmarusti V, Van Boemel G, Dagnelie G, de Juan E. Visual perception in a blind subject with a chronic microelectronic retinal prosthesis. Vision Res. 2003; 43:2573-2581.
80. Zarbin MA, Rosenfeld PJ. Pathway-based therapies for age-related macular degeneration: An integrated survey of emerging treatment alternatives. Retina. 2010; 30: 1350-1367.